Neuro Precision STALICLA is a clinical-stage biopharma focusing on Neuro Precision Medicine for neurodevelopmental and neuropsychiatric disorders, signaling opportunities to collaborate on targeted therapies, companion diagnostics, and precision trial services with pharma, biotechs, and contract research organizations.

ASD and SUD Active programs span Autism Spectrum Disorder and Substance Use Disorder with Phase 2 readiness for ASD subgroup-matched treatments (STP1) and Phase 3 efforts for cocaine use disorder (STP7) in collaboration with NIDA, offering partnership and licensing possibilities around specialized drug candidates and study designs.

Strategic Fundraising Recent fundraising activity and leadership changes indicate a capital readiness window; potential investors or strategic partners could explore co-development, milestone-based financing, or joint development agreements to accelerate late-stage trials and platform expansion.

Clinical Leadership New appointments in chairmanship, scientific and clinical advisory, and medical leadership signal a maturing governance and execution capability, creating opportunities for CROs, advisory partnerships, and academic collaborations to support trial execution and regulatory strategy.

Collaborative Potential Existing partnerships with Evgen and ongoing NIDA collaboration suggest a recruitment-friendly environment for further alliances on trial delivery, data monetization, and multi-omics DEPI platform applications to expand into additional neurodevelopmental or neuropsychiatric indications.